Have a personal or library account? Click to login
The Risk/Benefit Analysis of Oral Anticoagulant Treatment in Atrial Fibrillation Using HAS-BLED and CHA2DS2-VASc Score Cover

The Risk/Benefit Analysis of Oral Anticoagulant Treatment in Atrial Fibrillation Using HAS-BLED and CHA2DS2-VASc Score

Acta Marisiensis - Seria Medica
Volume 61 (2015): Issue 4 (December 2015)
By: Silivastru (Cozlea) Ionela,  Cozlea Daniel Laurentiu,  Keresztesi Arthur Attila,  Asofie Gabriela,  Cozlea Laurentiu,  Oltean Galafteon and  Dobru Daniela  
Open Access
|Jan 2016
DOI: https://doi.org/10.1515/amma-2015-0056 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Journal RSS Feed
Language: English
Page range: 269 - 272
Submitted on: Dec 9, 2014
|
Accepted on: Jun 4, 2015
|
Published on: Jan 19, 2016
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
atrial fibrillation,
thromboembolic events,
bleeding events,
oral anticoagulant treatment
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2016 Silivastru (Cozlea) Ionela, Cozlea Daniel Laurentiu, Keresztesi Arthur Attila, Asofie Gabriela, Cozlea Laurentiu, Oltean Galafteon, Dobru Daniela, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 61 (2015): Issue 4 (December 2015)Next article